Renascience Inc. Logo

Renascience Inc.

Develops innovative drugs and AI-powered medical devices for aging and hereditary diseases.

4889 | T

Overview

Corporate Details

ISIN(s):
JP3981100005
LEI:
Country:
Japan
Address:
仙台市青葉区星陵町2−1
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

Renascience Inc. is a research and development company engaged in the development and commercialization of pharmaceuticals and medical devices. The company focuses on creating innovative treatments derived from basic research to address various medical issues, including diseases associated with aging and hereditary conditions. Its R&D pipeline includes new drug candidates, such as antisense oligonucleotides, and advanced medical technology, such as a programmed medical device that utilizes artificial intelligence (AI) to support hemodialysis. Renascience actively forms strategic collaborations with pharmaceutical partners and academic institutions to advance its development projects and bring novel therapies to market.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-12 07:39
Report Publication Announcement
確認書
Japanese 8.7 KB
2025-11-12 07:37
Interim Report
半期報告書-第27期(2025/04/01-2026/03/31)
Japanese 434.5 KB
2025-09-03 08:37
Regulatory News Service
確認書
Japanese 8.7 KB
2025-09-03 08:30
Regulatory News Service
訂正有価証券報告書-第26期(2024/04/01-2025/03/31)
Japanese 1.7 MB
2025-06-27 08:35
Post-Annual General Meeting Information
臨時報告書
Japanese 23.6 KB
2025-06-24 08:36
Governance Information
内部統制報告書-第26期(2024/04/01-2025/03/31)
Japanese 23.2 KB
2025-06-24 08:35
Registration Form
確認書
Japanese 8.7 KB
2025-06-24 08:33
Registration Form
有価証券報告書-第26期(2024/04/01-2025/03/31)
Japanese 3.5 MB
2024-11-14 07:37
Interim Report
確認書
Japanese 8.7 KB
2024-11-14 07:36
Interim Report
半期報告書-第26期(2024/04/01-2025/03/31)
Japanese 288.9 KB
2024-06-28 04:56
Post-Annual General Meeting Information
臨時報告書
Japanese 24.5 KB
2024-06-28 04:32
Governance Information
内部統制報告書-第25期(2023/04/01-2024/03/31)
Japanese 22.7 KB
2024-06-28 04:26
Registration Form
確認書
Japanese 8.7 KB
2024-06-28 04:24
Annual Report
有価証券報告書-第25期(2023/04/01-2024/03/31)
Japanese 3.5 MB
2024-05-27 10:10
Board/Management Information
臨時報告書
Japanese 22.4 KB

Automate Your Workflow. Get a real-time feed of all Renascience Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Renascience Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Renascience Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

OSCOTECInc. Logo
A clinical-stage drug discovery company developing innovative medicines for unmet needs.
South Korea
039200
OSE Immunotherapeutics Logo
Develops first-in-class immune therapies for oncology and inflammation, partnering for late-stage.
France
OSE
Oxurion NV Logo
Acquires European pharmaceutical subcontractors to build an integrated healthcare services group.
Belgium
OXUR
PA Co., Ltd Logo
Offers HR solutions like recruitment media, staffing, and childcare to revitalize local communities.
Japan
4766
Passage BIO, Inc. Logo
Developing genetic medicines for severe CNS and neurodegenerative disorders.
United States of America
PASG
PCI Biotech Holding Logo
Biopharma firm evaluating its future after discontinuing its core technology development.
Norway
PCIB
PC İLETİŞİM VE MEDYA HİZMETLERİ SANAYİ TİCARET A.Ş. Logo
Integrated media group providing data-driven advertising and media solutions for global brands.
Türkiye
PCILT
PDS Biotechnology Corp Logo
Developing T-cell activating immunotherapies for cancer and infectious diseases.
United States of America
PDSB
Peers Co.,Ltd. Logo
Accelerating tech adoption with consulting, HR services, and proprietary IT/AI solutions.
Japan
7066
PepGen Inc. Logo
Biotech using an EDO platform to treat genetic neuromuscular & neurological diseases.
United States of America
PEPG

Talk to a Data Expert

Have a question? We'll get back to you promptly.